All In Biotech

Drug Trial Radar · NCT05091567

A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer

A Phase III, Randomized, Open-Label, Multicenter Study of Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab as Maintenance Therapy in Participants With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following First-Line Induction Therapy With Carboplatin, Etoposide and Atezolizumab

Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 660 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

660

Actual

Start

Nov 18, 2021

Primary completion

Jul 29, 2024

Study completion Feb 28, 2028

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
Jazz Pharmaceuticals
First posted
Oct 25, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study GO43104 is a Phase III, randomized, open-label, multicenter study of lurbinectedin in combination with atezolizumab compared with atezolizumab alone administered as maintenance therapy in participants with extensive-stage small-cell lung cancer (ES-SCLC) after first-line induction therapy with carboplatin, etoposide, and atezolizumab. The study consists of 2 phases: an induction phase and a maintenance phase. Participants need to have an ongoing response or stable disease per the Response Evaluation Criteria in Solid Tumor (RECIST) v1.1 criteria after completion of 4 cycles of carboplatin, etoposide, and atezolizumab induction treatment in order to be considered for eligibility screening for the maintenance phase. Eligible participants will be randomized in a 1:1 ratio to receive either lurbinectedin plus atezolizumab or atezolizumab in the maintenance phase.

Conditions

  • Small-Cell Lung Cancer

Interventions

  • AtezolizumabDrug

    Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle for 4 cycles in the induction phase. Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle in the maintenance phase.

  • LurbinectedinDrug

    Lurbinectedin 3.2 mg/m² will be administered intravenously on Day 1 of each 21-day cycle in the maintenance phase.

  • CarboplatinDrug

    Carboplatin will be administered according to the standard of care treatment for 4 cycles in the induction phase.

  • EtoposideDrug

    Etoposide will be administered according to the standard of care treatment for 4 cycles in the induction phase.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Randomized Phase: Independent Review Facility (IRF) - Assessed Progression Free Survival (PFS)Time frame: Up to 26 months
  2. Randomized Phase: Overall Survival (OS)Time frame: Up to 26 months

Locations

93 sites in 13 countries. Site status is shown where the registry gives one.

  • Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital

    Marietta, Georgia

  • Illinois Cancer Care

    Peoria, Illinois

  • New England Cancer Specialists

    Scarborough, Maine

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Cancer & Hematology Centers of Western Michigan

    Grand Rapids, Michigan

  • Clinical Research Alliance

    Westbury, New York

  • The Mark H. Zangmeister Ctr

    Columbus, Ohio

  • Rhode Island Hospital

    Providence, Rhode Island

  • Hollings Cancer Center

    Charleston, South Carolina

  • Greco-Hainesworth Centers for Research

    Chattanooga, Tennessee

  • West Clinic

    Germantown, Tennessee

  • Sarah Cannon Research Institute / Tennessee Oncology

    Nashville, Tennessee

  • Institut Jules Bordet

    Anderlecht, Belgium

  • Jessa Zkh (Campus Virga Jesse)

    Hasselt, Belgium

  • UZ Leuven Gasthuisberg

    Leuven, Belgium

  • AZ St Maarten Campus Leopoldstr

    Mechelen, Belgium

  • CHU UCL Mont-Godinne

    Mont-godinne, Belgium

  • Vitaz

    Sint-Niklaas, Belgium

  • Zentralklinik Bad Berka GmbH

    Bad Berka, Germany

  • Evang. Lungenklinik Berlin Klinik für Pneumologie

    Berlin, Germany

  • Helios Klinikum Emil von Behring GmbH

    Berlin, Germany

  • Klinikum Chemnitz gGmbH

    Chemnitz, Germany

  • KEM/Evang. Kliniken Essen Mitte gGmbH

    Essen, Germany

  • Niels-Stensen-Kliniken Franziskus-Hospital Harderberg GmbH

    Georgsmarienhütte, Germany

  • LungenClinic Großhansdorf GmbH

    Großhansdorf, Germany

  • Krankenhaus Martha-Maria Halle-Doelau gGmbH

    Halle, Germany

  • Fachklinik für Lungenerkrankungen

    Immenhausen, Germany

  • Universitätsklinikum Schleswig-Holstein

    Lübeck, Germany

  • Asklepios Klinik Gauting

    München-Gauting, Germany

  • Sotiria Thoracic Diseases Hospital of Athens

    Athens, Greece

  • Errikos Dynan Hospital

    Athens, Greece

  • University Hospital of Larissa

    Larissa, Greece

  • Euromedical General Clinic of Thessaloniki

    Thessaloniki, Greece

  • Ag. Loukas Hospital

    Thessaloniki, Greece

  • Diavalkaniko Hospital

    Thessaloniki, Greece

  • Orszagos Koranyi Pulmonologiai Intezet

    Budapest, Hungary

  • Pécsi Tudományegyetem

    Pécs, Hungary

  • Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rend.Int.

    Szolnok, Hungary

  • Tudogyogyintezet Torokbalint

    Törökbálint, Hungary

  • AUSL della Romagna

    Ravenna, Emilia-Romagna, Italy

Showing 40 of 93 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.